United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond Sells 7,792 Shares

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,792 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $355.88, for a total transaction of $2,773,016.96. Following the transaction, the chief financial officer now owns 5,884 shares in the company, valued at approximately $2,093,997.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

James Edgemond also recently made the following trade(s):

• On Monday, October 7th, James Edgemond sold 7,794 shares of United Therapeutics stock. The stock was sold at an average price of $355.54, for a total transaction of $2,771,078.76.
• On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The stock was sold at an average price of $358.62, for a total transaction of $2,794,367.04.
• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $359.57 on Wednesday. The company has a 50-day moving average of $348.11 and a 200-day moving average of $306.02. The company has a market capitalization of $16.00 billion, a price-to-earnings ratio of 16.52, a PEG ratio of 1.29 and a beta of 0.57. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $366.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. United Therapeutics’s revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the business posted $5.24 earnings per share. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kapitalo Investimentos Ltda lifted its holdings in United Therapeutics by 69.4% during the 3rd quarter. Kapitalo Investimentos Ltda now owns 1,470 shares of the biotechnology company’s stock valued at $527,000 after purchasing an additional 602 shares during the last quarter. Creative Planning lifted its holdings in United Therapeutics by 8.9% during the 3rd quarter. Creative Planning now owns 3,935 shares of the biotechnology company’s stock valued at $1,410,000 after purchasing an additional 322 shares during the last quarter. CHICAGO TRUST Co NA bought a new position in United Therapeutics during the 3rd quarter valued at about $204,000. Ritholtz Wealth Management lifted its holdings in United Therapeutics by 14.3% during the 3rd quarter. Ritholtz Wealth Management now owns 839 shares of the biotechnology company’s stock valued at $301,000 after purchasing an additional 105 shares during the last quarter. Finally, Private Advisory Group LLC bought a new position in United Therapeutics during the 3rd quarter valued at about $987,000. 94.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

UTHR has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. Bank of America lowered their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley lowered shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $357.17.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.